Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » Protokinetix on the move??

 - UBBFriend: Email this page to someone!    
Author Topic: Protokinetix on the move??
jackbequick
Member


Rate Member
Icon 14 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
Volume for Protokinetix shot up to 700K Friday. Talk of Conference Calls on other PKTX Message boards about possible PR News out this week? PKTX 10-K, quarterly report, out too. Could get exciting.

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
Questions & Answers for Protokinetix investors...
Still adding PKTX (otcbb) last weeks, full position now since two weeks.

Latest company outlook, all depends on wether they get a deal or not.Basically shell company now with management and one key product. IP patents on it. No overhead costs due to that, most suppliers/consultancy payed in shares in the past. Waiting for them to sign a deal. Deal pending since early 2009, talks with L'oreal in 2009.

Good risk reward due to the unique compound. Accumulating this year.

See great potential in living tissue transport outside the body (5 days standard care there, their product kan keep tissue good for 5-30 days), as well as for skin care/cosmetic products ingredient.
Personally feel the latter might be the big pot of gold for them and i also judge that they should be able to sign a deal on it.

Last year talks with L' Oreal as mentioned and l'oreal filed for a patent for use of some of their products together with protokinetix compound if i read all correctly.

ProtoKinetix Questions and Answers:

- Can one see the stem cell technology as a part of the biotechnology spectrum or should one consider it as a separate �industry�?
It is definitely a part of the biotechnology industry known as regenerative medicine. It is generally recognized as an extremely promising and emerging approach to a variety of diseases that have the potential to be treated.

- Where does the world stand in the research process of the stem cell technology?
Major inroads have been made by several research groups in the differentiation of stem cells into other cells for therapeutic purposes such as islet cells and hepatocytes. Additionally research into the effective harvesting, storage, amplification and recovery of stem cells is well developed.

- How long will it last until we see really a �marketable product�?
Stem cell therapy for the treatment of certain cancers such as leukemia and lymphomahave been available now for several years. The likelihood of therapies for other cancers as well as diabetes and heart disease in the very near future 12-24 months is also very high.

- Do you have any figure what amount of seed capital has been burned by research of the stem cell companies since the real beginning?
Sorry, no idea but it is an enormous figure when you factor in the major pharmaceutical companies, universities, medical foundations, hospitals as well as the specialty bio-tech companies and government initiatives.

- Tell me something about the willingness of venture capitalist to finance further research efforts of the stem cell industry in the current economic environment?
The venture capital firms that specialize in biotech tend towards a long term and high return philosophy and traditionally have done very well, there appears to be no shortage of capital for any valid promising approach to a new therapy. In addition there are of course the medical foundations that are extensive investors into new research.


- Concerning PKTX what area in stem cell technology and research are you in?
Stem cells are by their very nature very sensitive and delicate. When they are stored at cryo temperatures of -196 Celsius the recovery loss can be extremely high. The AAGP molecule dramatically enhances the recovery rate. Further, in the case that stem cells are used for differentiation into other cells for disease treatment, the AAGP molecule provides a pivotal role in the protection of these new cells during transplantation.


- What in detail are synthetic anti-aging glycopeptides? What are they good for?
The AAGP family of molecules has demonstrated the most powerful defense mechanism for all cell lines tested against the most hostile of conditions. When cells are attacked. whether by toxins, radiation, trauma, fatigue or famine they become subject to inflammation and quickly die. In the presence of a small amount of the AAGP molecule the death of the cell can be delayed by as much as 400%.

The AAGP molecule is a small (580 dalton) synthetic glycopeptides, which is a derivative of a naturally occurring far larger anti-freeze glycoprotein.

The potential medical uses for AAGP include but are not limited to:
Stem cell therapies, Diabetes, Inflammatory diseases, Ischemia, skin care, organ transplants, blood storage.

- Let�s assume you can produce a viable product tell me something about your potential customers?
For the therapeutic applications, the potential customers would be joint venture partners / licensees. For the skin care and dermatological uses, the logical consumers would be geographical / industry specific licensees. It is expected that ProtoKinetix is a prime takeover target.

- How long will it last until you really can come to the market with a viable product?
With all the research and testing completed to date, the family of AAGP� molecules is ready for commercialization now.

- What is your yearly burn rate and what is your financial position?
ProtoKinetix� yearly burn rate is under $200,000.00 USD. The company has been financed mostly by family and friends through Private Placements.

- Do you need further money to finish your research efforts? No further research investment is required to bring the product to certain markets. The Company does however, have the potential to develop more advanced versions of AAGP� under their existing patents.


- Is there any dialog with the major players from the pharmaceutical and healthcare industry regarding any kind of license agreement or equity participation?
There is considerable dialog with major players presently in progress, but there is not presently an announceable partnership or licensing agreement in place.


- Give me some information about your management?
ProtoKinetix� management is divided between strategic and tactical. The strategic management is headed up by Dr. Edward Martin who is the Chairman of our Business Advisory Board. Admiral Dr. Edward Martin, Chairman of Martin Blanek and Associates, has extensive experience in the field of pharmaceutical drug development. The head of tactical operations is CEO and President, Ross L. Senior. Mr. Senior is a well know attorney who headed up the Canadian Advanced Technology Association.


- What is your shareholder structure? What percentage of the share capital is hold by the management? What is the free float? Do you have any institutional shareholders?
ProtoKinetix has roughly 70-million shares outstanding with approximately 35% held by management, friends and long term corporate supporters. Other than 1-reporting institutional shareholder, ProtoKinetix is widely held by individual investors.

-What are your expectations for the share price over the next 24-months?

Over the next 2-years, the Company should attain a market capitalization of over $1-Billion USD which could be expected to realize a share price well in excess of $5.00PPS...

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
This is from another message board, Interesting.....This Chapter in science..Might be where Protokinetix's product...AAGP. Could be a very big factor with it's strong Anti-Inflammatory properies.....Regenerative Medicine is the process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. This field holds the promise of regenerating damaged tissues and organs in the body by stimulating previously irreparable organs to heal themselves. Regenerative medicine also empowers scientists to grow tissues and organs in the laboratory and safely implant them when the body cannot heal itself. Importantly, regenerative medicine has the potential to solve the problem of the shortage of organs available for donation compared to the number of patients that require life-saving organ transplantation, as well as solve the problem of organ transplant rejection, since the organ's cells will match that of the patient.

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
PKTX New Horizons
Interesting thought on PKTX.
(PKTX)..What the Heck, PKTX Investors!
....What did the Malta Skin-Ageing Conf.,of August 18,of 2009..Accomplish??�It was Exposure, BABY! After that conference....(Jan.,22/10..Protokinetix was approached by a European biopharma investment group with a series of proposals to develop commercial partnerships in the pharmaceutical/cosmetic arenas. In order to support these initiatives, it has been strongly suggested that our European technology (AAGP�) should be more visibly showcased within the European community. This would include an awareness program leading up to a sponsorship for a listing on the AIM, London Stock Exchange.
.....Do you think PKTX�s product AAGP maybe got some exposure due to �The Malta Skin-Ageing Conf.,�???
....With all the positive �Exposures� over the last year or more, not to point out all the great research that Protokinetixs has done in the last six years and still on going��
....Though the lines of Exposure�PKTX�.Has a following in the European community(Germany)..This German PR Newsletter(Prospectus)is a �light turned on�, that (IMHO)Protokinetix/European) has a growing(Global) interest with PKTX�s product�AAGP.
.....With "read-this-n0ws�(IHUB Poster) findings of the German PR Newsletter..(High-Lighting PKTX�s research with AAGP)�and yes, it is in German..(IMHO)..Hopefully, this will be short-lived and the English translation will be added for English Protokinetix investors�..Everybody have a great weekend�It�s time for PKTX to �Rock-N-Roll� in this world�.It�s Exposure,Baby!..It�s Protokinetix!
http://home.xmsnet.nl/privatebanking/Alp...
If an PKTX investor want to view the German PKTX PR Newsletter(which is in German) go to "IHUB PKTX site"...

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
(PKTX)..This is the English/German Translation for the German PKTX PR Newsletter..Just remember, Folks..Protokinetix, is going Global(European)...Hope Has a Name – August 2010

Investors are searching for one company dealing in stem cell research that is going
to profit in the stock market. The search is still going on and is now concentrating
on the North American market. The management of Canada's ProtoKinetix, Inc. believes
that the initial phase of research is over and in due course they will earn money on
the market with interesting products. This is not only in the area of stem cell
research.

ProtoKinetix was founded in 2004. Since this time the company has done numerous
scientific studies, not only in the stem cell preservation, but also in stem cell
therapies with commercial possibilities. PKTX invented in the last years a new
family of synthetic anti-aging-glyco proteins under the name of AAGP™. These
proteins will find in the next step their way into skin therapy and cosmetics as
well as in medicine and biotechnology. The most important success factor for
ProtoKinetix is their AAGP™ technology. This family of molecules was developed by
Dr. Geraldine Castelot-DellienCourt and the French INSA (Institute for Scientific
Application). The procedure and usage are protected by global patents. Geraldine
Castelot-Deliencour won in the year 2006 the highest French scientific award:
Francinov.

The family of molecules that ProtoKinetix developed, known as AAGP™, is the basis
for the new products which can be used in the following fields:

? Stem Cell Technology
? Skin Care Therapy / cosmetics
? Medicine (preservation, storage and transplantation of cells, tissue and organs)

ProtoKinetix has reached very positive test results that, according to experts, are
astonishing. Stem cells are often used in Cyropreservation-procedures - frozen to
minus 196 Grad Celsius (centigrade) and stored using DMSO™. Stem Cells are very
sensitive to negative environmental influences. The functions and survival of human
cells in everyday life is complicated with a lot of different factors like
environment, age and diseases. This is also true for cold - so cells will often die
in the Cryopreservation process. The addition of the AAGP™ to this process
produces very promising results in the view of stability and health as well as life
expectancy. The tests showed under these acute stressful circumstances that the
sensitive cells showed very good development.

We are observing the AAGP™ technology treatments as "anti-inflammatory" lotions
which are able to protect the skin from negative influences and the aging of the
skin can be slowed down. ?

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
From PKTX 10-K..Very recently
Note this line in "Recent Developments" section of 10K report, released yesterday:
"The Company is currently both negotiating and engaged with a number of companies under collaboration and material transfer agreements for the purposes of research and product development and out-licensing.

The companies are working in mutually exclusive areas."

This is the first time I have seen this statement in the quarterly report, and leads me to believe they may be close to negotiating an agreement or agreements that would lead to commercialization of the PKTX AAGP technology.

Good luck to all PKTX investors!

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
Press Release Source: ProtoKinetix, Inc. On Thursday September 23, 2010, 7:00 am EDT
VANCOUVER--(BUSINESS WIRE)--ProtoKinetix Inc. (PKTX), over the last several weeks, has been in discussions with several diabetes specific organizations with a view to testing in 2-key areas in the treatment of diabetes. The company believes that AAGP™ will play a key role in potential treatment for Type 1 and Type 2 Diabetes.

Previous independently conducted in-vivo testing clearly demonstrated the importance of AAGP™ in islet cell transplantation. With recent developments from a variety of stem cell companies, the differentiation of stem cells into islets is, today, a reality. This success helps to overcome the limitations inherent in islet cell transplantations including the severe shortage of donor pancreases and the necessity for anti-rejection drugs when foreign islet cells are transplanted into recipients.

Both of these limitations have the potential to be eliminated with the development of successful differentiation of patient’s own stem cells. Testing to date has shown that the success of the transplant is dramatically improved by the addition of AAGP™ to the transplanted islet cells.

Type 1 Diabetes (Juvenile or early onset) is an auto-immune disease in which the insulin producing beta cells (islets) are destroyed by antibodies over time. Over the past few years, ProtoKinetix has tested a large variety of human cell lines under a wide range of hostile conditions. In every case, the cell lines that were treated with AAGP™ benefited from a significant extension of viable cell life.

The Company believes that AAGP™ has demonstrated the ability to provide a powerful layer of protection against the hostility of these auto-immune antibodies. Any postponement of the clinical symptoms of diabetes provides a major health benefit for diabetics. There is a strong potential for this molecule to play a pivotal part in the effective treatment of diabetes.

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
PKTX looks to run tests for new possible Diabetes treatment





ProtoKinetix Inc (PKTX) Eyes Independent Analysis of Potential Breakthrough Treatments for Juvenile Diabetes, As Well As Type I and II Adult Onset Diabetes

ProtoKinetix Inc. (PKTX) is communicating with several independent organizations with key roles in the research and development of experimental diabetes treatments, to discuss the potential limitations involved with testing in 2-key diabetes treatment areas. The company believes, after extensive internal research and testing, that their proprietary AAGP™ will play a key role in potential treatment for Type 1 and Type 2 Diabetes.


Previous independently conducted in-vivo testing clearly demonstrated the importance of AAGP™ in islet cell transplantation. With recent developments from a variety of stem cell companies, the differentiation of stem cells into islets is, today, a reality. This success helps to overcome the limitations inherent in islet cell transplantations including the severe shortage of donor pancreases and the necessity for anti-rejection drugs when foreign islet cells are transplanted into recipients.


Both of these limitations have the potential to be eliminated with the development of successful differentiation of patient's own stem cells. Testing to date has shown that the success of the transplant is dramatically improved by the addition of AAGP™ to the transplanted islet cells.


Type 1 Diabetes (Juvenile or early onset) is an auto-immune disease in which the insulin producing beta cells (islets) are destroyed by antibodies over time. Over the past few years, ProtoKinetix has tested a large variety of human cell lines under a wide range of hostile conditions. In every case, the cell lines that were treated with AAGP™ benefitted from a significant extension of viable cell life.


The Company believes that AAGP™ has demonstrated the ability to provide a powerful layer of protection against the hostility of these auto-immune antibodies. Any postponement of the clinical symptoms of diabetes provides a major health benefit for diabetics. There is a strong potential for this molecule to play a pivotal part in the effective treatment of diabetes.

ProtoKinetix, Incorporated, a biotechnology company, engages in the research, development, and testing of a family of synthetic anti-aging glycopeptides (AAGPs) for enhancing the health and extending the life of biologically sensitive cells. The commercial applications of AAGPs include harvesting, storage, and transplantation of cells, tissues, and organs; and treatments for conditions and disease caused by stress factors, including UV radiation, starvation, oxidation, temperature, and inflammation. The company was founded in 1999 and is based in Vancouver, Canada.

--------------------
The check is in the mail...

Posts: 129 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share